Safe 6-thioguanine therapy of a TPMT deficient Crohn's disease patient by using therapeutic drug monitoring

被引：11
作者：
Mares, W. G. N. [1 ]
Wong, D. R. [2 ]
Gilissen, L. P. L. [3 ]
Masclee, A. A. M. [1 ]
Hooymans, P. M. [2 ]
Engels, L. G. J. B. [4 ]
机构：
[1] Maastricht Univ, Dept Gastroenterol & Hepatol, Med Ctr, Maastricht, Netherlands
[2] Orbis Med Ctr, Dept Clin Pharm, Sittard Geleen, Netherlands
[3] Catharino Hosp Eindhoven, Dept Gastroenterol, Eindhoven, Netherlands
[4] Orbis Med Ctr, Dept Gastroenterol, Sittard Geleen, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2009年 / 3卷 / 02期
关键词：
Crohns disease; Drug therapy; Inflammatory bowel disease; Thiopurines; Therapeutic drug monitoring; INFLAMMATORY-BOWEL-DISEASE; 6-MERCAPTOPURINE THERAPY; AZATHIOPRINE THERAPY; THIOPURINE; THIOGUANINE; TOXICITY; EFFICACY; TERM;
D O I：
10.1016/j.crohns.2009.02.002
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
The immunosuppressive thiopurines, azathioprine (AZA) and 6-mercaptopurine (6-MP), have proven efficacy in steroid-dependant or refractory inflammatory bowel disease (IBD). In case of TPMT deficiency serious myelosuppression may occur. 6-thioguanine (6-TG), has been suggested in case of AZA and 6-MP resistant or intolerant patients. Our case demonstrates that very low dose 6-TG under close clinical surveillance and frequent therapeutic drug monitoring, may be a rescue drug for IBD-patients with tow or without functional TPMT activity. (C) 2009 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：128 / 130
页数：3
相关论文
共 16 条
[1]  
ADLER DJ, 1990, AM J GASTROENTEROL, V85, P717
[2]   Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease [J].
Cuffari, C ;
Hunt, S ;
Bayless, T .
GUT, 2001, 48 (05) :642-646
[3]   On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients [J].
de Boer, Nanne K. H. ;
Derijks, Luc J. J. ;
Gilissen, Lennard P. L. ;
Hommes, Daniel W. ;
Engels, Leopold G. J. B. ;
de Boer, Sybrand Y. ;
den Hartog, Gijsbertus ;
Hooymans, Piet M. ;
Makelburg, Anja B. U. ;
Westerveld, Barend D. ;
Naber, Anton H. J. ;
Mulder, Chris J. J. ;
de Jong, Dirk J. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (35) :5540-5544
[4]   Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease - Implications for therapy [J].
Derijks, LJJ ;
Gilissen, LPL ;
Engels, LGJB ;
Bos, LP ;
Bus, PJ ;
Lohman, JJHM ;
Curvers, WL ;
van Deventer, SJH ;
Hommes, DW ;
Hooymans, PM .
THERAPEUTIC DRUG MONITORING, 2004, 26 (03) :311-318
[5]   6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment [J].
Derijks, LJJ ;
de Jong, DJ ;
Gilissen, LPL ;
Engels, LGJB ;
Hooymans, PM ;
Jansen, JBMJ ;
Mulder, CJJ .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (01) :63-67
[6]   Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease [J].
Dubinsky, MC ;
Lamothe, S ;
Yang, HY ;
Targan, SR ;
Sinnett, D ;
Théorêt, Y ;
Seidman, EG .
GASTROENTEROLOGY, 2000, 118 (04) :705-713
[7]   Thioguanine: A potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine [J].
Dubinsky, MC ;
Feldman, EJ ;
Abreu, MT ;
Targan, SR ;
Vasiliauskas, EA .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (05) :1058-1063
[8]   An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy [J].
Dubinsky, MC ;
Hassard, PV ;
Seidman, EG ;
Kam, LY ;
Abreu, MT ;
Targan, SR ;
Vasiliauskas, EA .
INFLAMMATORY BOWEL DISEASES, 2001, 7 (03) :181-189
[9]   Toxicity of 6-thioguanine:: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine -: Some evidence for dose or metabolite level dependent effects? [J].
Gilissen, L. P. L. ;
Derijks, L. J. J. ;
Driessen, A. ;
Bos, L. P. ;
Hooymans, P. M. ;
Stockbrugger, R. W. ;
Engels, L. G. J. B. .
DIGESTIVE AND LIVER DISEASE, 2007, 39 (02) :156-159
[10]   Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy [J].
Gilissen, LPL ;
Derijks, LJJ ;
Bos, LP ;
Bus, PJ ;
Hooymans, PM ;
Engels, LGJB .
CLINICAL DRUG INVESTIGATION, 2004, 24 (08) :479-486
12